GB2428577A - Free radical scavenging wound powder - Google Patents
Free radical scavenging wound powder Download PDFInfo
- Publication number
- GB2428577A GB2428577A GB0515787A GB0515787A GB2428577A GB 2428577 A GB2428577 A GB 2428577A GB 0515787 A GB0515787 A GB 0515787A GB 0515787 A GB0515787 A GB 0515787A GB 2428577 A GB2428577 A GB 2428577A
- Authority
- GB
- United Kingdom
- Prior art keywords
- urate
- free radical
- wound
- healing
- spheres
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000843 powder Substances 0.000 title claims abstract description 10
- 230000007760 free radical scavenging Effects 0.000 title description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 22
- 206010052428 Wound Diseases 0.000 claims abstract description 9
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 7
- 229940116269 uric acid Drugs 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000035876 healing Effects 0.000 claims abstract description 6
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 4
- 229960000458 allantoin Drugs 0.000 claims abstract description 4
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 108010092464 Urate Oxidase Proteins 0.000 claims abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000003357 wound healing promoting agent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 230000003389 potentiating effect Effects 0.000 abstract description 4
- 150000003254 radicals Chemical class 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 230000002491 angiogenic effect Effects 0.000 abstract description 2
- 239000003963 antioxidant agent Substances 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 150000001768 cations Chemical class 0.000 abstract description 2
- 239000002516 radical scavenger Substances 0.000 abstract description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 229940072107 ascorbate Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- -1 free radical peroxynitrite Chemical class 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 2
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 2
- 240000002299 Symphytum officinale Species 0.000 description 2
- 235000005865 Symphytum officinale Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Uric acid as monovalent urate is a potent endogenous antioxidant protecting against free radical damage in man and other animals. The free radical peroxynitrite is implicated in non-healing chronic wounds. Urate is a most efficient scavenger of peroxynitrite forming a reduced radical capable of regeneration back into urate in the presence of ascorbate or thiols. Uricase a ubiquitous enzyme, although absent in human tissues, converts urate to allantoin the latter having potent angiogenic wound healing properties. Persistent bacteria, common in chronic non-healing wounds, would generate allantoin from topically applied urate. Synthetic urate spheres formed in a cation rich aqueous solution at ambient temperature, are extracted in ethanol and air-dried to the wound powder. These spheres show stability in various physiological media and added to the low solubility of urate, ensures prolonged local tissue activity; also precluding the risk of systemic absorption causing gout, although excessive application may cause local irritation.
Description
The Description.
Title: Free radical seaven2in2 wound powder.
Background:
Uric acid is recognised as a potent natural antioxidant in living tissues (l3ecker 1993).
with a specific role as a free radical scavenger protecting endothelial nitric oxide synthase (eNOS) a major enzyme involved in wound healing (Kuzkaya Ct al 2005).
Uric acid also may be beneficial to ameliorate glucose-induced diabetic deleiioiation (Cheng-Chin Hsu et al 2005). An oxidative breakdown product of uric acid is the angiogenic allantoin the active constituent of Comfrey (Swnphytwn officinale) alias Knit Bone', which since classical times is reported to having beneficial healing properties. Spherulitic uric acid (urate spheres') form in aqueous solution under high cation concentrations (Mc Nabb 1980), these sphere are size modulated (<SOpm) and do not coalesce in alcohol or dry powder form, giving even dispeisal characteristics a major advantage over simple ground samples Urate spheres made by this method show remarkable stability in various physiological environments and are well tolerated in open skin wounds allowing for the possibility of tissue incorporation (unpublished own work 2005).
Essential features: Spherulitic urate as a potent free radical scavenging wound healing powder application for treatment of chronic non-healing ulcerative wounds typical of diabetes mellitus and venous leg ulcers.
Method: Uric acid is converted into spherulitic urate under saturated aqueous conditions using concentrated sodium hydroxide at room temperature. The aqueous phase is replaced by absolute ethanol (98%), preserving these urate spheres; followed by evaporative drying giving a dry powder of urate spheres. This dry powder is used for direct application to open wounds prior surgical closure in order to suppress chronic non- healing the result of excess free radicals.
Claims (3)
- CLAIMS.I. A topical wound powder composed of dry synthetic urate spheres for the application to open wounds to promote healing.
- 2. Synthetic urate spheres claimed in Claim I made by mixing aqueous solutions of saturate uric acid and concentrated sodium hydroxide replacing the aqueous phase with ethanol and drying to a fme powder.
- 3. A wound powder claimed in Claim 1 or Claim 2 that in the presence of uricase of bacterial origin generates allantoin a wound-healing agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0515787A GB2428577A (en) | 2005-08-01 | 2005-08-01 | Free radical scavenging wound powder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0515787A GB2428577A (en) | 2005-08-01 | 2005-08-01 | Free radical scavenging wound powder |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0515787D0 GB0515787D0 (en) | 2005-09-07 |
GB2428577A true GB2428577A (en) | 2007-02-07 |
Family
ID=34983865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0515787A Withdrawn GB2428577A (en) | 2005-08-01 | 2005-08-01 | Free radical scavenging wound powder |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2428577A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262020B1 (en) * | 2000-02-15 | 2001-07-17 | Alphamed Pharmaceuticals Corp. | Topical wound therapeutic compositions |
US20010041684A1 (en) * | 2000-02-15 | 2001-11-15 | John Lezdey | Topical wound therapeutic compositions |
WO2004096367A1 (en) * | 2003-04-28 | 2004-11-11 | Ustav Makromolekularni Chemie Akademie Ved Ceske Republiky | A wound-cover material containing radical scavengers |
-
2005
- 2005-08-01 GB GB0515787A patent/GB2428577A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262020B1 (en) * | 2000-02-15 | 2001-07-17 | Alphamed Pharmaceuticals Corp. | Topical wound therapeutic compositions |
US20010041684A1 (en) * | 2000-02-15 | 2001-11-15 | John Lezdey | Topical wound therapeutic compositions |
WO2004096367A1 (en) * | 2003-04-28 | 2004-11-11 | Ustav Makromolekularni Chemie Akademie Ved Ceske Republiky | A wound-cover material containing radical scavengers |
Also Published As
Publication number | Publication date |
---|---|
GB0515787D0 (en) | 2005-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103041438B (en) | Moist antibacterial hydrogel dressing for curing diabetic foot ulcer | |
CN103271794B (en) | Biological antibiotic based on bedsore wound is applied ointment or plaster | |
DE602004005188T2 (en) | SKIN COMPOSITIONS WITH AN OXIDOREDUCETASE ENZYME | |
US20220288134A1 (en) | Composition, system and method for treating skin | |
US20100284951A1 (en) | Novel compositions for the treatment of wounds and skin care | |
CN110051602B (en) | Skin moistening, moisturizing and repairing emulsion and preparation method thereof | |
CN105107007A (en) | Cationic medical wound protecting dressing and method for preparing same | |
CN112245652A (en) | Bacteriostatic liquid band-aid capable of quickly forming film and preparation method thereof | |
CN114343975A (en) | Wet wound dressing and its prepn | |
GB2428577A (en) | Free radical scavenging wound powder | |
CN102178930A (en) | Anti-acne composition containing epidermal growth factors and tea tree oil and preparation method thereof | |
CN106139229A (en) | A kind of novel antibacterial aerogel dressing and preparation method thereof | |
US6923990B2 (en) | Stabilized silver-ion amine complex compositions and methods | |
CN112076339B (en) | Antibacterial band-aid containing zinc oxide nanoparticles and preparation method thereof | |
CN105169463B (en) | A kind of cation baby's medical dressing and preparation method thereof | |
US5616619A (en) | Topical composition for burn relief and method of use | |
WO2005077402A1 (en) | Honey based gel formulations | |
CN113289055A (en) | Green liquid adhesive bandage with antibacterial function and preparation method thereof | |
Faoagali | Use of antiseptics in managing difficult wounds | |
CN104474584B (en) | A kind of preparation method of nano composite antibacterial dressing | |
CN104258457A (en) | Abelmoschus manihot oil gauze | |
CN207693777U (en) | A kind of novel water-absorbing resin wound application | |
RU2132193C1 (en) | Preparation for treatment and disinfection of skin and mucosa membranes | |
CA2480889A1 (en) | External preparation for wounds | |
CN105796401A (en) | Bacteria resisting and inflammation diminishing jelly mask |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |